Literature DB >> 29556816

The Role of Cardiovascular Magnetic Resonance in the Management of Patients with Cancer.

W Gregory Hundley1,2,3.   

Abstract

PURPOSE OF REVIEW: This article reviews the utility of cardiovascular magnetic resonance imaging (CMR) to detect abnormalities of the cardiovascular system that may result from cancer or its treatment. RECENT
FINDINGS: With CMR, one may assess cardiac anatomy, function, myocardial perfusion, tissue composition, and blood flow. For those with cancer, these capabilities allow one to differentiate myocardial masses that may relate to the presence of cancer and evaluate diseases of the pericardium. These features facilitate measurement of left ventricular (LV) volumes, ejection fraction, mass, strain, T1 and T2 relaxation properties, and the extracellular volume fraction all of which may be useful for detecting subclinical cardiovascular injury that results from the receipt of potentially cardiotoxic cancer treatment. CMR can provide an effective and efficient means to identify clinical abnormalities resulting from the diagnosis of cancer or subclinical cardiac injury that may be related to receipt of the therapy for cancer.

Entities:  

Keywords:  Cancer; Cardiovascular magnetic resonance; Imaging

Year:  2018        PMID: 29556816     DOI: 10.1007/s11936-018-0626-y

Source DB:  PubMed          Journal:  Curr Treat Options Cardiovasc Med        ISSN: 1092-8464


  42 in total

Review 1.  T1 Mapping in Characterizing Myocardial Disease: A Comprehensive Review.

Authors:  Valentina O Puntmann; Elif Peker; Y Chandrashekhar; Eike Nagel
Journal:  Circ Res       Date:  2016-07-08       Impact factor: 17.367

2.  Cardiovascular magnetic resonance imaging for diagnosis and clinical management of suspected cardiac masses and tumours.

Authors:  Sandra Fussen; Bart W L De Boeck; Michael J Zellweger; Jens Bremerich; Kaatje Goetschalckx; Michel Zuber; Peter T Buser
Journal:  Eur Heart J       Date:  2011-04-15       Impact factor: 29.983

Review 3.  Cardiac MRI in the assessment of cardiac injury and toxicity from cancer chemotherapy: a systematic review.

Authors:  Paaladinesh Thavendiranathan; Bernd J Wintersperger; Scott D Flamm; Thomas H Marwick
Journal:  Circ Cardiovasc Imaging       Date:  2013-11       Impact factor: 7.792

4.  Value of CMR for the differential diagnosis of cardiac masses.

Authors:  Pablo Pazos-López; Eduardo Pozo; Maria E Siqueira; Inés García-Lunar; Matthew Cham; Adam Jacobi; Frank Macaluso; Valentín Fuster; Jagat Narula; Javier Sanz
Journal:  JACC Cardiovasc Imaging       Date:  2014-08-13

5.  Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101-Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity.

Authors:  Edith Pituskin; John R Mackey; Sheri Koshman; Davinder Jassal; Marshall Pitz; Mark J Haykowsky; Joseph J Pagano; Kelvin Chow; Richard B Thompson; Larissa J Vos; Sunita Ghosh; Gavin Y Oudit; Justin A Ezekowitz; D Ian Paterson
Journal:  J Clin Oncol       Date:  2016-11-28       Impact factor: 44.544

6.  Relation of acute pericardial disease to malignancy.

Authors:  Massimo Imazio; Brunella Demichelis; Iris Parrini; Elisa Favro; Federico Beqaraj; Enrico Cecchi; Franco Pomari; Daniela Demarie; Aldo Ghisio; Riccardo Belli; Marco Bobbio; Rita Trinchero
Journal:  Am J Cardiol       Date:  2005-06-01       Impact factor: 2.778

7.  Myxoma of the mitral valve: diagnosis by 2-dimensional and 3-dimensional echocardiography.

Authors:  M Handke; A Schöchlin; D M Schäfer; F Beyersdorf; A Geibel
Journal:  J Am Soc Echocardiogr       Date:  1999-09       Impact factor: 5.251

8.  Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors.

Authors:  Jennifer H Jordan; Sujethra Vasu; Timothy M Morgan; Ralph B D'Agostino; Giselle C Meléndez; Craig A Hamilton; Andrew E Arai; Songtao Liu; Chia-Ying Liu; João A C Lima; David A Bluemke; Gregory L Burke; W Gregory Hundley
Journal:  Circ Cardiovasc Imaging       Date:  2016-08       Impact factor: 7.792

9.  Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines.

Authors:  Tomas G Neilan; Otavio R Coelho-Filho; Diego Pena-Herrera; Ravi V Shah; Michael Jerosch-Herold; Sanjeev A Francis; Javid Moslehi; Raymond Y Kwong
Journal:  Am J Cardiol       Date:  2012-08-21       Impact factor: 2.778

10.  The association between cardiovascular risk and cardiovascular magnetic resonance measures of fibrosis: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Colin J Yi; Colin O Wu; Michael Tee; Chia-Ying Liu; Gustavo J Volpe; Martin R Prince; Gregory W Hundley; Antoinette S Gomes; Rob J van der Geest; Susan Heckbert; João A Lima; David A Bluemke
Journal:  J Cardiovasc Magn Reson       Date:  2015-02-12       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.